A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer

NCT03873402 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

437

Enrollment

INDUSTRY

Sponsor class

Conditions

Renal Cell Carcinoma

Interventions

BIOLOGICAL: Nivolumab
BIOLOGICAL: Ipilimumab
OTHER: Ipilimumab placebo

Sponsor

Bristol-Myers Squibb